8 results on '"Salah Eldin Hussein"'
Search Results
2. The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates
- Author
-
Nawal Al Kaabi, Abderrahim Oulhaj, Farida Ismail Al Hosani, Shamma Al Mazrouei, Omer Najim, Salah Eldin Hussein, Jehad Saleh Abdalla, Mohammed Saifuddin Fasihuddin, Afnan Abdellatif Hassan, Gehad Elghazali, Ahmed Al Rumaithi, Jumana Al Azazi, Stefan Weber, Rami Beiram, Khatija A. Parekh, Mohamud Sheek-Hussein, Yunkai Yang, Yang Xiaoming, Jenny Quliang, Islam Eltantawy, Sally Mahmoud, Ashish Koshy, Peng Xiao, Subhashini Ganesan, Wael Elamin, and Walid Zaher
- Subjects
Medicine ,Science - Abstract
Abstract Based on the findings from the Phase III clinical trials of inactivated SARS COV-2 Vaccine, (BBIBP-CORV) emergency use authorization (EUA) was granted for the vaccine to frontline workers in the UAE. A prospective cohort study was conducted among frontline workers to estimate the incidence rate and risk of symptomatic COVID-19 infection 14 days after the second dose of inoculation with BBIBP-CORV inactivated vaccine. Those who received two doses of the BBIBP-CORV vaccine in the period from 14th of September 2020 (first dose) to 21st of December 2020 (second dose) were followed up for COVID-19 infections. 11,322 individuals who received the two-dose BBIBP-CORV vaccine were included and were followed up post the second dose plus fourteen days. The incidence rate of symptomatic infection was 0.08 per 1000-person days (95% CI 0.07, 0.10). The estimated absolute risk of developing symptomatic infection was 0.97% (95% CI 0.77%, 1.17%). The confirmed seroconversion rate was 92.8%. There were no serious adverse events reported and no individuals suffered from severe disease. Our findings show that vaccinated individuals are likely to remain protected against symptomatic infection or becoming PCR positive for SARS COV 2 following the second dose of the vaccination.
- Published
- 2022
- Full Text
- View/download PDF
3. Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi
- Author
-
Nawal Al Kaabi, Yunkai Yang, Salah Eldin Hussein, Tian Yang, Jehad Abdalla, Hui Wang, Zhiyong Lou, Chinese Center for Disease Control and Prevention, Agyad Bakkour, Afnan Arafat, China National Biotec Group Company Limited, Zhiwei Jiang, Ye Tian, National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd., Beijing Institute of Biological Products Company Limited, Peng Xiao, Walid Zaher, Islam Eltantawy, Chenlong Wang, Guangxue Xu, Yuntao Zhang, and Xiaoming Yang
- Subjects
inactivated vaccines ,COVID-19 ,SARS-CoV-2 ,booster dose ,phase 3 trial ,Medicine - Abstract
Importance: The protective efficacy of COVID-19 vaccinations has declined over time such that booster doses are required. Objective: To evaluate the efficacy and adverse events of booster doses of two inactivated COVID-19 vaccines. Design: This is a double-blind, randomized, placebo-controlled phase 3 trial aiming to evaluate the protective efficacy, safety, and immunogenicity of inactivated SARS-CoV-2 vaccine (Vero cells) after inoculation with booster doses of inactivated COVID-19 vaccine. Setting: Healthy volunteers were recruited in an earlier phase 3 trial of two doses of inactivated vaccine. The participants in Abu Dhabi maintained the blind state of the trial and received a booster dose of vaccine or placebo at least six months after the primary immunization. Participants: Adults aged 18 and older with no history of SARS-CoV, SARS-CoV-2, or Middle East respiratory syndrome infection (via onsite inquiry) were screened for eligibility. Interventions: A total of 9370 volunteers were screened and randomly allocated, of which 61 voluntarily withdrew from the screening stage without booster inoculation; 9309 received the booster vaccination, with 3083 in the WIV04 group, 3150 in the HB02 group, and 3076 in the alum-only group. Further, 5μg and 4μg of inactivated SARS-CoV-2 virion was adsorbed into aluminum hydroxide in a 0.5 mL aqueous suspension for WIV04 and HB02 vaccines. Main Outcomes and Measures: The primary efficacy outcome was the prevention of PCR-confirmed symptomatic COVID-19 from 14 days after the booster vaccine in the per-protocol population. A safety analysis was performed in the intention-to-treat population. Results: Symptomatic COVID-19 was identified in 36 participants in the WIV04 group (9.9 [95% CI, 7.2–13.8] per 1000 person-years), 28 in the HB02 group (7.6 [95% CI, 5.2–11.0] per 1000 person-years), and 193 in the alum-only group (55.2 [95% CI, 47.9–63.5] per 1000 person-years), resulting in a vaccine efficacy of 82.0% (95% CI, 74.2–87.8%) for WIV04 and 86.3% (95% CI, 79.6–91.1%) for HB02. One severe case of COVID-19 occurred in the alum-only group, and none occurred in the vaccine groups. Adverse reactions within seven days after vaccination occurred in 29.4% to 34.3% of participants in the three groups. Serious adverse events were rare and not related to vaccines (WIV04: 17 [0.5%]; HB02: 11 [0.4%]; alum only: 40 [1.3%]). Conclusions and Relevance: This study evaluated the safety of the booster dose, which was well tolerated by participants. Booster doses given over six months after the completion of primary immunization can help to provide more-effective protection against COVID-19 in healthy people 18 years of age or older. At the same time, the anti-SARS-CoV-2 antibodies produced by the two groups of experimental vaccines exhibited extensive cross-neutralization against representative SARS-CoV-2 variants. Trial Registration: This study is registered on ClinicalTrials.gov (NCT04510207).
- Published
- 2023
- Full Text
- View/download PDF
4. Safety and Immunogenicity of the NVX-CoV2373 Vaccine as a Booster in Adults Previously Vaccinated with the BBIBP-CorV Vaccine: An Interim Analysis
- Author
-
Seth Toback, Anthony M. Marchese, Brandy Warren, Sondos Ayman, Senka Zarkovic, Islam ElTantawy, Raburn M. Mallory, Matthew Rousculp, Fahed Almarzooqi, Bartlomiej Piechowski-Jozwiak, Maria-Fernanda Bonilla, Agyad Ebrahim Bakkour, Salah Eldin Hussein, and Nawal Al Kaabi
- Abstract
This phase 3 observer-blind, randomized, controlled study was conducted in adults ≥18 years of age to assess the safety and immunogenicity of NVX-CoV2373 as a heterologous booster compared to BBIBP-CorV when utilized as a homologous booster. Approximately 1,000 participants were randomly assigned in a 1:1 ratio to receive a single dose of NVX-CoV2373 or BBIBP-CorV after prior vaccination with 2 or 3 doses of BBIBP-CorV. Solicited adverse events (AEs) were collected for 7 days after vaccination. Unsolicited AEs were collected for 28 days following the booster dose and serious adverse and adverse events of special interest (AESI) were collected throughout the study. For this interim analysis, anti-spike IgG and neutralizing antibodies against SARS-CoV-2 were measured at baseline, day 14, and day 28. The study achieved its primary non-inferiority endpoint and also demonstrated statistically higher neutralization responses of approximately 6-fold when NVX-CoV2373 was utilized as a heterologous booster compared with BBIBP-CorV as a homologous booster. Both vaccines had an acceptably low reactogenicity profile and no new safety concerns were found. Heterologous boosting with NVX-CoV2373 was a highly immunogenic and safe vaccine regimen in those previously vaccinated with BBIBP-CorV.
- Published
- 2023
5. Assessing and addressing barriers towards MDI use in acute asthma exacerbations at a tertiary pediatric ED in the United Arab Emirates
- Author
-
Malcolm Borg, Salah Eldin Hussein, Nida Fatima Sakrani, and Sofia Konstantinopoulou
- Subjects
medicine.medical_specialty ,050402 sociology ,Asthma exacerbations ,business.industry ,Moderate asthma ,05 social sciences ,Psychological intervention ,Emergency department ,medicine.disease ,Clinical Practice ,03 medical and health sciences ,0302 clinical medicine ,0504 sociology ,030225 pediatrics ,Family medicine ,Pediatrics, Perinatology and Child Health ,medicine ,Medical prescription ,business ,Asthma ,Cohort study - Abstract
Asthma is one of the most common causes of emergency department (ED) visits in children. Therapy delivered through a meter dose inhaler with spacer (MDI + S) is equally as effective as nebulization in mild and moderate asthma exacerbations but was not routinely prescribed in the ED at the largest tertiary center for pediatrics in the United Arab Emirates (UAE). Phase 1 of this cohort study involved a validated survey to evaluate physicians' knowledge, attitudes and perceptions towards MDI therapy. While 62% of physicians reported that MDI + S was equally effective as nebulizers and 82% believed that they had sufficient knowledge with regard to its use, only 28% prescribed it. Perceived barriers to change of practice included: Lack of clinical practice guidelines (CPG), poor knowledge amongst nurses and physicians, caregivers' reluctance and a difficult prescription process. Phase 2 consisted of administering the same survey after completing interventions to address the aforementioned barriers. Comparisons were made between the subgroups within phase 1 and statistically significant differences were noted with a p value .05. The number of physicians who prescribed MDI + S increased from 28% to 41% (p value = .046). Moreover, physicians who believed that convincing parents to use MDI + S therapy would be easy, increased from 35% to 66% (p value .0001). In conclusion, more physicians reported prescribing MDI + S in Phase 2 while concerns about barriers that exist to change in practice remained similar in both phases showing that consistent and prolonged advocacy is required to achieve long-term compliance.
- Published
- 2022
6. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial
- Author
-
Wei Wang, Islam Eltantawy, Yuxiu Zhao, Hui Wang, Salah Eldin Hussein, Majed Al Nusair, Shamma K Al Mazrouei, Jaleela S Jawad, Walid Abbas Zaher, Yan-Bo Zhang, Sally Mahmoud, Xinguo Li, Shengli Xia, Wei Chen, Guoqing Zhao, Zhiqiang Xie, Wangyang You, Yuntao Zhang, Xuqin Yang, Tian Yang, Xiaoming Yang, Zaidoon M Hussain, Peng Xiao, Maysoon Al Karam, An Pan, Manaf M Al Qahtani, Najiba Abdulrazzaq, Mohammed Saifuddin Fasihuddin, Rui Ma, Kai Duan, Tehmina Khan, Mohamed Hassany, Shihe Huang, Nawal Al Kaabi, Jehad Abdalla, Yunkai Yang, Qian Wang, Bonan Lai, Ashish Koshy, Liu Yang, and Zhiwei Jiang
- Subjects
Adult ,Male ,medicine.medical_specialty ,Randomization ,COVID-19 Vaccines ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Datasets as Topic ,01 natural sciences ,Injections, Intramuscular ,law.invention ,03 medical and health sciences ,Middle East ,0302 clinical medicine ,Immunogenicity, Vaccine ,Randomized controlled trial ,Double-Blind Method ,law ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,0101 mathematics ,Adverse effect ,Original Investigation ,business.industry ,Incidence (epidemiology) ,010102 general mathematics ,COVID-19 ,General Medicine ,Middle Aged ,Interim analysis ,Vaccine efficacy ,Clinical trial ,Vaccines, Inactivated ,Female ,business - Abstract
IMPORTANCE: Although effective vaccines against COVID-19 have been developed, additional vaccines are still needed. OBJECTIVE: To evaluate the efficacy and adverse events of 2 inactivated COVID-19 vaccines. DESIGN, SETTING, AND PARTICIPANTS: Prespecified interim analysis of an ongoing randomized, double-blind, phase 3 trial in the United Arab Emirates and Bahrain among adults 18 years and older without known history of COVID-19. Study enrollment began on July 16, 2020. Data sets used for the interim analysis of efficacy and adverse events were locked on December 20, 2020, and December 31, 2020, respectively. INTERVENTIONS: Participants were randomized to receive 1 of 2 inactivated vaccines developed from SARS-CoV-2 WIV04 (5 µg/dose; n = 13 459) and HB02 (4 µg/dose; n = 13 465) strains or an aluminum hydroxide (alum)–only control (n = 13 458); they received 2 intramuscular injections 21 days apart. MAIN OUTCOMES AND MEASURES: The primary outcome was efficacy against laboratory-confirmed symptomatic COVID-19 14 days following a second vaccine dose among participants who had no virologic evidence of SARS-CoV-2 infection at randomization. The secondary outcome was efficacy against severe COVID-19. Incidence of adverse events and reactions was collected among participants who received at least 1 dose. RESULTS: Among 40 382 participants randomized to receive at least 1 dose of the 2 vaccines or alum-only control (mean age, 36.1 years; 32 261 [84.4%] men), 38 206 (94.6%) who received 2 doses, contributed at least 1 follow-up measure after day 14 following the second dose, and had negative reverse transcriptase–polymerase chain reaction test results at enrollment were included in the primary efficacy analysis. During a median (range) follow-up duration of 77 (1-121) days, symptomatic COVID-19 was identified in 26 participants in the WIV04 group (12.1 [95% CI, 8.3-17.8] per 1000 person-years), 21 in the HB02 group (9.8 [95% CI, 6.4-15.0] per 1000 person-years), and 95 in the alum-only group (44.7 [95% CI, 36.6-54.6] per 1000 person-years), resulting in a vaccine efficacy, compared with alum-only, of 72.8% (95% CI, 58.1%-82.4%) for WIV04 and 78.1% (95% CI, 64.8%-86.3%) for HB02 (P
- Published
- 2021
7. Properties of the characteristic polynomials and spectrum of Pn and Cn
- Author
-
Salah Eldin Hussein, Essam El Seidy, and Atef Mohamed
- Subjects
Discrete mathematics ,Degree matrix ,Hollow matrix ,Spectral graph theory ,Incidence matrix ,010103 numerical & computational mathematics ,Mathematics::Spectral Theory ,01 natural sciences ,Combinatorics ,Graph energy ,Seidel adjacency matrix ,Adjacency matrix ,0101 mathematics ,Laplacian matrix ,Mathematics - Abstract
We consider a finite undirected and connected simple graph with vertex set and edge set .We calculated the general formulas of the spectra of a cycle graph and path graph. In this discussion we are interested in the adjacency matrix, Laplacian matrix, signless Laplacian matrix, normalized Laplacian matrix, and seidel adjacency matrix.
- Published
- 2016
8. Graded Essential Extensions and Graded Injective Modules
- Author
-
Salah Eldin Hussein, Essam El Seidy, and H. S. Diab
- Subjects
Pure mathematics ,Mathematics::Commutative Algebra ,Mathematics::Rings and Algebras ,Graded ring ,General Earth and Planetary Sciences ,Injective hull ,Indecomposability ,Injective module ,Injective function ,General Environmental Science ,Mathematics - Abstract
In this paper we establish the relation between graded essential extensions of graded modules and injectivity of such modules. We relate the graded injective hull Egr (M) of a graded module M with the graded essential extensions of M. We round off by establishing necessary and sufficient conditions for indecomposability of graded injective modules in terms of their graded injective hulls.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.